Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
6.42
USD
|
+4.39%
|
|
-0.47%
|
-23.84%
|
Fiscal Period: Marzo |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
481.7
|
365.4
|
1,419
|
801.6
|
1,001
|
394.1
|
-
|
-
|
Enterprise Value (EV)
1 |
353.4
|
365.4
|
942.2
|
405.9
|
1,001
|
134.9
|
227.2
|
394.1
|
P/E ratio
|
-11.4
x
|
-6.47
x
|
-17.4
x
|
-7.51
x
|
-5.91
x
|
-2.03
x
|
-2.23
x
|
-2.46
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
64.4
x
|
12.3
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
37.1
x
|
12.3
x
|
EV / EBITDA
|
-11,475,235
x
|
-
|
-
|
-3,494,179
x
|
-5,729,311
x
|
-
|
-
|
-
|
EV / FCF
|
-12.6
x
|
-5.45
x
|
-14.8
x
|
-4.8
x
|
-7.68
x
|
-0.75
x
|
-1.04
x
|
-2.19
x
|
FCF Yield
|
-7.92%
|
-18.4%
|
-6.77%
|
-20.8%
|
-13%
|
-133%
|
-96.6%
|
-45.7%
|
Price to Book
|
3.49
x
|
1.99
x
|
2.85
x
|
1.95
x
|
1.8
x
|
1.07
x
|
1.27
x
|
-
|
Nbr of stocks (in thousands)
|
31,647
|
36,646
|
46,493
|
47,206
|
56,655
|
61,388
|
-
|
-
|
Reference price
2 |
15.22
|
9.970
|
30.51
|
16.98
|
17.66
|
6.420
|
6.420
|
6.420
|
Announcement Date
|
6/28/19
|
6/3/20
|
5/20/21
|
5/19/22
|
5/18/23
|
-
|
-
|
-
|
Fiscal Period: Marzo |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
6.121
|
32.01
|
EBITDA
|
-30.8
|
-
|
-
|
-116.2
|
-174.6
|
-
|
-
|
-
|
EBIT
1 |
-30.95
|
-56.2
|
-79.96
|
-118.3
|
-177.1
|
-227
|
-220.7
|
-215.3
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,605.06%
|
-672.6%
|
Earnings before Tax (EBT)
1 |
-30.83
|
-52.62
|
-80.87
|
-118
|
-174
|
-212
|
-230.7
|
-225.4
|
Net income
1 |
-30.83
|
-52.62
|
-80.87
|
-118
|
-174.3
|
-213.1
|
-225.5
|
-225.4
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,684.38%
|
-704.38%
|
EPS
2 |
-1.330
|
-1.540
|
-1.750
|
-2.260
|
-2.990
|
-3.170
|
-2.878
|
-2.613
|
Free Cash Flow
1 |
-27.98
|
-67.09
|
-63.78
|
-84.52
|
-130.3
|
-179.5
|
-219.5
|
-180
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,585.82%
|
-562.39%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
6/28/19
|
6/3/20
|
5/20/21
|
5/19/22
|
5/18/23
|
-
|
-
|
-
|
Fiscal Period: March |
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 Q3
|
2025 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-29.25
|
-29.7
|
-31.99
|
-40.88
|
-41.58
|
-41.63
|
-53
|
-55.65
|
-63.83
|
-56.54
|
-56.06
|
-57.93
|
-58.84
|
-60.11
|
-61.42
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-29.36
|
-29.67
|
-31.7
|
-42.25
|
-43.1
|
-39.69
|
-48.95
|
-49.35
|
-60.24
|
-50.65
|
-52.93
|
-54.76
|
-56.05
|
-56.81
|
-58.54
|
Net income
1 |
-29.36
|
-29.67
|
-31.7
|
-42.25
|
-43.1
|
-39.69
|
-49.24
|
-49.56
|
-60.04
|
-51.12
|
-53.59
|
-54.41
|
-54.44
|
-54.11
|
-54.43
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.5600
|
-0.5700
|
-0.6000
|
-0.7800
|
-0.7900
|
-0.6900
|
-0.7400
|
-0.7500
|
-0.9000
|
-0.7700
|
-0.8042
|
-0.7998
|
-0.7774
|
-0.7882
|
-0.7972
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/4/21
|
2/3/22
|
5/19/22
|
8/4/22
|
11/3/22
|
2/9/23
|
5/18/23
|
8/3/23
|
11/7/23
|
2/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
128
|
-
|
476
|
396
|
-
|
259
|
167
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-28
|
-67.1
|
-63.8
|
-84.5
|
-130
|
-180
|
-220
|
-180
|
ROE (net income / shareholders' equity)
|
-56.2%
|
-32.7%
|
-23.4%
|
-27.8%
|
-36.1%
|
-46%
|
-40.8%
|
-
|
ROA (Net income/ Total Assets)
|
-28.1%
|
-27.1%
|
-20.6%
|
-24.9%
|
-31.5%
|
-38.6%
|
-36.3%
|
-
|
Assets
1 |
109.7
|
194.2
|
393
|
473.2
|
553.9
|
552.1
|
621.7
|
-
|
Book Value Per Share
2 |
4.360
|
5.010
|
10.70
|
8.690
|
9.800
|
6.000
|
5.070
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
2.6
|
6.54
|
2.39
|
2.34
|
2.27
|
4
|
4
|
4
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
65.35%
|
12.5%
|
Announcement Date
|
6/28/19
|
6/3/20
|
5/20/21
|
5/19/22
|
5/18/23
|
-
|
-
|
-
|
Last Close Price
6.42
USD Average target price
13.56
USD Spread / Average Target +111.15% Consensus |
1st Jan change
|
Capi.
|
---|
| -23.84% | 394M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|